Seek Returns logo

HLN vs. INSM: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at HLN and INSM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

HLN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, INSM is a standard domestic listing.

SymbolHLNINSM
Company NameHaleon plcInsmed Incorporated
CountryUnited KingdomUnited States
GICS SectorConsumer StaplesHealth Care
GICS IndustryPersonal Care ProductsBiotechnology
Market Capitalization40.25 billion USD34.20 billion USD
ExchangeNYSENasdaqGS
Listing DateJuly 25, 2022June 1, 2000
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of HLN and INSM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

HLN vs. INSM: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolHLNINSM
5-Day Price Return-0.84%5.90%
13-Week Price Return-11.02%67.73%
26-Week Price Return-14.92%120.66%
52-Week Price Return-12.92%129.52%
Month-to-Date Return-0.63%12.36%
Year-to-Date Return-12.48%134.37%
10-Day Avg. Volume16.58M2.19M
3-Month Avg. Volume14.61M3.35M
3-Month Volatility19.16%32.12%
Beta0.451.01

Profitability

Return on Equity (TTM)

HLN

3.26%

Personal Care Products Industry

Max
33.29%
Q3
19.04%
Median
10.69%
Q1
3.26%
Min
-10.45%

HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.

INSM

-195.37%

Biotechnology Industry

Max
97.92%
Q3
11.99%
Median
-19.30%
Q1
-51.29%
Min
-132.03%

INSM has a negative Return on Equity of -195.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

HLN vs. INSM: A comparison of their Return on Equity (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

HLN

12.84%

Personal Care Products Industry

Max
14.65%
Q3
10.84%
Median
9.29%
Q1
5.35%
Min
-0.14%

A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.

INSM

-259.82%

Biotechnology Industry

Max
73.34%
Q3
18.98%
Median
-12.96%
Q1
-105.72%
Min
-259.82%

INSM has a negative Net Profit Margin of -259.82%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

HLN vs. INSM: A comparison of their Net Profit Margin (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

HLN

19.64%

Personal Care Products Industry

Max
19.64%
Q3
16.46%
Median
12.80%
Q1
8.01%
Min
2.98%

An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

INSM

-252.41%

Biotechnology Industry

Max
78.85%
Q3
21.90%
Median
-13.30%
Q1
-109.94%
Min
-278.10%

INSM has a negative Operating Profit Margin of -252.41%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

HLN vs. INSM: A comparison of their Operating Profit Margin (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Profitability at a Glance

SymbolHLNINSM
Return on Equity (TTM)3.26%-195.37%
Return on Assets (TTM)1.58%-49.49%
Net Profit Margin (TTM)12.84%-259.82%
Operating Profit Margin (TTM)19.64%-252.41%
Gross Profit Margin (TTM)60.75%75.72%

Financial Strength

Current Ratio (MRQ)

HLN

0.87

Personal Care Products Industry

Max
4.03
Q3
2.73
Median
1.76
Q1
1.16
Min
0.76

HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

INSM

6.68

Biotechnology Industry

Max
16.97
Q3
8.39
Median
4.11
Q1
2.64
Min
0.74

INSM’s Current Ratio of 6.68 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

HLN vs. INSM: A comparison of their Current Ratio (MRQ) against their respective Personal Care Products and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

HLN

0.53

Personal Care Products Industry

Max
1.80
Q3
0.78
Median
0.30
Q1
0.04
Min
0.00

HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

INSM

0.45

Biotechnology Industry

Max
1.92
Q3
0.79
Median
0.12
Q1
0.00
Min
0.00

INSM’s Debt-to-Equity Ratio of 0.45 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

HLN vs. INSM: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Personal Care Products and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

HLN

8.00

Personal Care Products Industry

Max
96.53
Q3
59.91
Median
22.25
Q1
7.85
Min
-3.28

HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.

INSM

-27.79

Biotechnology Industry

Max
72.37
Q3
1.03
Median
-9.59
Q1
-65.05
Min
-163.11

INSM has a negative Interest Coverage Ratio of -27.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

HLN vs. INSM: A comparison of their Interest Coverage Ratio (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Financial Strength at a Glance

SymbolHLNINSM
Current Ratio (MRQ)0.876.68
Quick Ratio (MRQ)0.636.13
Debt-to-Equity Ratio (MRQ)0.530.45
Interest Coverage Ratio (TTM)8.00-27.79

Growth

Revenue Growth

HLN vs. INSM: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

HLN vs. INSM: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

HLN

0.72%

Personal Care Products Industry

Max
4.99%
Q3
2.70%
Median
1.98%
Q1
0.95%
Min
0.00%

HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

INSM

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

HLN vs. INSM: A comparison of their Dividend Yield (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

HLN

954.40%

Personal Care Products Industry

Max
221.40%
Q3
137.27%
Median
70.48%
Q1
51.10%
Min
0.00%

At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

INSM

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

HLN vs. INSM: A comparison of their Dividend Payout Ratio (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Dividend at a Glance

SymbolHLNINSM
Dividend Yield (TTM)0.72%0.00%
Dividend Payout Ratio (TTM)954.40%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

HLN

20.40

Personal Care Products Industry

Max
46.28
Q3
31.71
Median
22.50
Q1
20.20
Min
11.79

HLN’s P/E Ratio of 20.40 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

INSM

--

Biotechnology Industry

Max
40.44
Q3
39.37
Median
22.12
Q1
15.76
Min
3.48

P/E Ratio data for INSM is currently unavailable.

HLN vs. INSM: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

HLN

2.62

Personal Care Products Industry

Max
2.59
Q3
2.35
Median
1.92
Q1
1.18
Min
0.00

With a P/S Ratio of 2.62, HLN trades at a valuation that eclipses even the highest in the Personal Care Products industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

INSM

86.14

Biotechnology Industry

Max
92.67
Q3
41.36
Median
8.45
Q1
4.46
Min
0.97

INSM’s P/S Ratio of 86.14 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

HLN vs. INSM: A comparison of their Price-to-Sales Ratio (TTM) against their respective Personal Care Products and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

HLN

2.11

Personal Care Products Industry

Max
12.00
Q3
6.22
Median
2.84
Q1
1.70
Min
1.12

HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

INSM

15.28

Biotechnology Industry

Max
22.72
Q3
10.68
Median
4.55
Q1
2.44
Min
0.59

INSM’s P/B Ratio of 15.28 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

HLN vs. INSM: A comparison of their Price-to-Book Ratio (MRQ) against their respective Personal Care Products and Biotechnology industry benchmarks.

Valuation at a Glance

SymbolHLNINSM
Price-to-Earnings Ratio (TTM)20.40--
Price-to-Sales Ratio (TTM)2.6286.14
Price-to-Book Ratio (MRQ)2.1115.28
Price-to-Free Cash Flow Ratio (TTM)13.68--